Quest Diagnostics (DGX) EBIT Margin (2009 - 2026)

Quest Diagnostics has reported EBIT Margin for 18 years, with the latest figure at 15.08% in Q2 2026.

• Quarterly EBIT Margin fell 78.0% year-over-year to 15.08% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 14.1% (up 8.0% YoY) and the FY2025 annual result came in at 14.1%, up 47.0% from the prior year.
• EBIT Margin grew to 15.08% in Q2 2026 per DGX's latest filing, from 13.78% in the prior quarter.
• Over five years, EBIT Margin peaked at 19.65% in Q1 2022 and troughed at 5.79% in Q4 2022.
• A 5-year average of 13.96% and a median of 13.78% in 2024 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2022 and 2023: EBIT Margin sank 1375 bps in 2022, then soared 588 bps in 2023.
• Over 5 years, EBIT Margin stood at 5.79% in 2022, then jumped by 102 bps to 11.67% in 2023, then rose by 18 bps to 13.77% in 2024, then retreated by 0 bps to 13.76% in 2025, then increased by 10 bps to 15.08% in 2026.
• According to Business Quant data, EBIT Margin over the past three periods registered 15.08%, 13.78%, and 13.76% for Q2 2026, Q1 2026, and Q4 2025 respectively.